Skip to content

Clinical study on the incidence of Adeno-associated virus 9 (AAV-9) Neutralizing antibody in Chinese patients with Duchenne muscular dystrophy

Clinical study on the incidence of Adeno-associated virus 9 (AAV-9) Neutralizing antibody in Chinese patients with Duchenne muscular dystrophy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400080977
Enrollment
Unknown
Registered
2024-02-19
Start date
2021-11-12
Completion date
Unknown
Last updated
2024-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy

Interventions

patients with Duchenne muscular dystrophy:NA

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Chinese male subjects diagnosed with DMD. The diagnosis conclusion of the subject must be recorded in his medical history, and must be confirmed by the Genetic testing results reported by the corresponding supervised laboratory using clinically verified Genetic testing methods for the purpose of disease diagnosis during routine clinical diagnosis and treatment. The results of Genetic testing must be able to confirm the existence of mutations in the dystrophin gene and be consistent with the diagnosis conclusion of DMD. 2. A signed and dated informed consent form and consent form (if applicable), which is used as evidence to show that the subject and his legal representative/parents/Legal guardian have been informed of all research related information. 3. Subjects and their Legal guardian are willing and able to participate in the planned laboratory examination and other research steps as required. Subjects agreed to participate in this study according to local regulations and the requirements of the Institutional review board (IRB).

Exclusion criteria

Exclusion criteria: 1. Other systemic Immunosuppressive drug other than glucocorticoids are being used. 2. The subject has previously used any gene therapy medication. 3. Family members of research center staff directly involved in the implementation of this study who are managed by the researcher, as well as research center staff who are not managed by the researcher, or family members of Pfizer employees directly involved in the implementation of this study.

Design outcomes

Primary

MeasureTime frame
The incidence of AAV9 NAb positivity in Chinese DMD subjects;

Secondary

MeasureTime frame
The frequency of aav9 nba positive and different titers in various demographic subgroups;

Countries

China

Contacts

Public ContactYuwu Jiang

Peking University First Hospital

jiangyw@263.net+86 137 0139 8992

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026